• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西黄丸联合化疗治疗乳腺癌疗效的Meta分析

Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer.

作者信息

Mao Dan, Feng Lei, Huang Siqi, Zhang Shaofan, Peng Weijun, Zhang Sifang

机构信息

Department of Integrated Traditional Chinese and Western Internal Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410000, China.

Department of Oncology, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, Hunan 410006, China.

出版信息

Evid Based Complement Alternat Med. 2019 Mar 12;2019:3502460. doi: 10.1155/2019/3502460. eCollection 2019.

DOI:10.1155/2019/3502460
PMID:30992708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6434299/
Abstract

OBJECTIVE

To systematically evaluate the efficacy of Xihuang pill (XHP) in breast cancer patients receiving chemotherapy.

METHODS

Three English and four Chinese databases were searched. Literature was screened using EndNote X7 and data were analyzed by Review Manager.

RESULTS

This review included 13 randomized clinical studies of 1272 patients. The results showed that XHP increased the tumor response [risk ratio (RR) = 2.91; 95% confidence interval (CI): 1.98-4.26] and improved Karnofsky performance score (KPS) for breast cancer patients receiving chemotherapy [RR = 4.96; 95% CI = 2.07-11.86]. In addition, XHP treatment significantly reduced chemotherapy-induced adverse events, including nausea and vomiting [RR = 0.50; 95% CI = 0.33-0.74], WBC reduction [RR = 0.71; 95% CI = 0.47-1.06], platelet reduction [RR = 0.53; 95% CI = 0.19-1.44], hemoglobin reduction [RR = 0.31; 95% CI = 0.19-0.52], and hepatic function damage [RR = 0.63; 95% CI = 0.35-1.11].

CONCLUSION

XHP combined with chemotherapy in comparison with chemotherapy alone could significantly enhance the tumor response, improve KPS, and alleviate toxicity induced by chemotherapy in breast cancer patients.

摘要

目的

系统评价西黄丸（XHP）在接受化疗的乳腺癌患者中的疗效。

方法

检索了三个英文数据库和四个中文数据库。使用EndNote X7进行文献筛选，并通过Review Manager进行数据分析。

结果

本综述纳入了13项随机临床研究，共1272例患者。结果显示，XHP提高了肿瘤反应率[风险比（RR）=2.91；95%置信区间（CI）：1.98 - 4.26]，并改善了接受化疗的乳腺癌患者的卡氏功能状态评分（KPS）[RR = 4.96；95% CI = 2.07 - 11.86]。此外，XHP治疗显著减少了化疗引起的不良事件，包括恶心和呕吐[RR = 0.50；95% CI = 0.33 - 0.74]、白细胞减少[RR = 0.71；95% CI = 0.47 - 1.06]、血小板减少[RR = 0.53；95% CI = 0.19 - 1.44]、血红蛋白减少[RR = 0.31；95% CI = 0.19 - 0.52]以及肝功能损害[RR = 0.63；95% CI = 0.35 - 1.11]。

结论

与单纯化疗相比，XHP联合化疗可显著增强乳腺癌患者的肿瘤反应，改善KPS，并减轻化疗所致毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/7d7c7c9b882b/ECAM2019-3502460.021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/34af9c6aeb4a/ECAM2019-3502460.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3eb6c13ae1e9/ECAM2019-3502460.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/88a3b9a73839/ECAM2019-3502460.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/625919dc5fe2/ECAM2019-3502460.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/36625726aa85/ECAM2019-3502460.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/393e28f76c40/ECAM2019-3502460.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/93d9f3fe7af3/ECAM2019-3502460.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/a174df3a060c/ECAM2019-3502460.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/76b593aeb467/ECAM2019-3502460.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/6e483b54454d/ECAM2019-3502460.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/329c1e5a99ac/ECAM2019-3502460.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/59ad8ce4952a/ECAM2019-3502460.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/8a56405f7a96/ECAM2019-3502460.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/525acd7f2789/ECAM2019-3502460.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/21c7782194a0/ECAM2019-3502460.015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3fa06de6618b/ECAM2019-3502460.016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/af84a14e5620/ECAM2019-3502460.017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/1d010842a74d/ECAM2019-3502460.018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3f22835021cc/ECAM2019-3502460.019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/538526fb35d5/ECAM2019-3502460.020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/7d7c7c9b882b/ECAM2019-3502460.021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/34af9c6aeb4a/ECAM2019-3502460.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3eb6c13ae1e9/ECAM2019-3502460.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/88a3b9a73839/ECAM2019-3502460.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/625919dc5fe2/ECAM2019-3502460.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/36625726aa85/ECAM2019-3502460.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/393e28f76c40/ECAM2019-3502460.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/93d9f3fe7af3/ECAM2019-3502460.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/a174df3a060c/ECAM2019-3502460.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/76b593aeb467/ECAM2019-3502460.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/6e483b54454d/ECAM2019-3502460.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/329c1e5a99ac/ECAM2019-3502460.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/59ad8ce4952a/ECAM2019-3502460.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/8a56405f7a96/ECAM2019-3502460.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/525acd7f2789/ECAM2019-3502460.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/21c7782194a0/ECAM2019-3502460.015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3fa06de6618b/ECAM2019-3502460.016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/af84a14e5620/ECAM2019-3502460.017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/1d010842a74d/ECAM2019-3502460.018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/3f22835021cc/ECAM2019-3502460.019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/538526fb35d5/ECAM2019-3502460.020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84e5/6434299/7d7c7c9b882b/ECAM2019-3502460.021.jpg

相似文献

1
Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer.西黄丸联合化疗治疗乳腺癌疗效的Meta分析
Evid Based Complement Alternat Med. 2019 Mar 12;2019:3502460. doi: 10.1155/2019/3502460. eCollection 2019.
2
The efficacy and safety of Xihuang Pill/capsule in adjuvant treatment of breast cancer: A systematic review and meta-analysis of 26 randomized controlled trials.西红花丸/胶囊辅助治疗乳腺癌的疗效和安全性：26 项随机对照试验的系统评价和荟萃分析。
J Ethnopharmacol. 2022 Sep 15;295:115357. doi: 10.1016/j.jep.2022.115357. Epub 2022 May 8.
3
Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis.健脾解毒中药在晚期结直肠癌患者中的应用：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2018 Jan 29;2018:6180810. doi: 10.1155/2018/6180810. eCollection 2018.
4
Exploring the Regulation Mechanism of Xihuang Pill, and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology.基于转录组学和化学信息学方法探索西黄丸及β-乳香酸对三阴性乳腺癌生物分子网络的调控机制
Front Pharmacol. 2020 Jun 11;11:825. doi: 10.3389/fphar.2020.00825. eCollection 2020.
5
Chinese Herbal Medicine as an Adjunctive Therapy for Breast Cancer: A Systematic Review and Meta-Analysis.中药作为乳腺癌的辅助治疗：系统评价和荟萃分析。
Evid Based Complement Alternat Med. 2016;2016:9469276. doi: 10.1155/2016/9469276. Epub 2016 May 9.
6
Kangai Injection, a Traditional Chinese Medicine, Improves Efficacy and Reduces Toxicity of Chemotherapy in Advanced Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.康艾注射液，一种中药，可提高晚期结直肠癌患者化疗的疗效并降低毒性：一项系统评价和荟萃分析。
Evid Based Complement Alternat Med. 2019 Jul 15;2019:8423037. doi: 10.1155/2019/8423037. eCollection 2019.
7
Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.消癌平注射液联合化疗治疗晚期胃癌的疗效与安全性：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2019 May 19;2019:3821053. doi: 10.1155/2019/3821053. eCollection 2019.
8
Efficacy of traditional Chinese Medicine combined with chemotherapy in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized clinical trials.中药联合化疗治疗非小细胞肺癌（NSCLC）患者的疗效：一项随机临床试验的荟萃分析
Support Care Cancer. 2020 Aug;28(8):3571-3579. doi: 10.1007/s00520-020-05433-w. Epub 2020 Apr 7.
9
Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms.西黄丸/胶囊辅助治疗宫颈癌的疗效与安全性的 Meta 分析。
Medicine (Baltimore). 2023 Aug 25;102(34):e34846. doi: 10.1097/MD.0000000000034846.
10
Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis.华蟾素联合化疗治疗晚期乳腺癌的疗效与安全性：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2020 Sep 19;2020:4953539. doi: 10.1155/2020/4953539. eCollection 2020.

引用本文的文献

1
Mechanism of Brucea javanica against multiple myeloma via TNF-NF-κB signaling.鸦胆子对多发性骨髓瘤通过肿瘤坏死因子-核因子κB信号通路的作用机制
Sci Rep. 2025 Jul 7;15(1):24311. doi: 10.1038/s41598-025-10271-z.
2
HIF1A acts as target of XiHuang Pill in the treatment of papillary thyroid cancer by regulating dedifferentiation.缺氧诱导因子1α（HIF1A）作为西黄丸治疗甲状腺乳头状癌去分化的作用靶点。
Front Chem. 2025 Jun 9;13:1607067. doi: 10.3389/fchem.2025.1607067. eCollection 2025.
3
Guidelines for the clinical application of the pill for the prevention and treatment of breast hyperplasia diseases.

本文引用的文献

1
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.来曲唑联合或不联合瑞博西林治疗激素受体阳性晚期乳腺癌的成本效果分析：基于中国人群的视角
Breast. 2019 Feb;43:1-6. doi: 10.1016/j.breast.2018.10.004. Epub 2018 Oct 16.
2
Traditional Chinese medicine is associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment.传统中医与接受多柔比星治疗的乳腺癌患者心力衰竭风险降低相关。
J Ethnopharmacol. 2019 Jan 30;229:15-21. doi: 10.1016/j.jep.2018.09.030. Epub 2018 Sep 25.
3
Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.
乳腺增生病防治丸临床应用指南。
Pharm Biol. 2024 Dec;62(1):472-479. doi: 10.1080/13880209.2024.2350233. Epub 2024 May 20.
4
Meta-analysis of the efficacy and safety of Xihuang Pills/capsules in adjuvant treatment of uterine cervical neoplasms.西黄丸/胶囊辅助治疗宫颈癌的疗效与安全性的 Meta 分析。
Medicine (Baltimore). 2023 Aug 25;102(34):e34846. doi: 10.1097/MD.0000000000034846.
5
Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of action of Wang Bu Liu Xing () for colorectal cancer.基于网络药理学预测和分子对接的策略探索王不留行治疗结直肠癌的潜在药理作用机制
J Gastrointest Oncol. 2023 Apr 29;14(2):504-515. doi: 10.21037/jgo-23-83. Epub 2023 Apr 24.
6
The prospect of pill in the treatment of cancers.药丸用于癌症治疗的前景。
Heliyon. 2023 Apr 14;9(4):e15490. doi: 10.1016/j.heliyon.2023.e15490. eCollection 2023 Apr.
7
Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.西黄丸通过抑制磷酸肌醇3激酶/蛋白激酶B/雷帕霉素作用靶点途径诱导肝癌细胞凋亡。
World J Gastrointest Oncol. 2022 Apr 15;14(4):872-886. doi: 10.4251/wjgo.v14.i4.872.
8
Study on the Potential Molecular Mechanism of Xihuang Pill in the Treatment of Pancreatic Cancer Based on Network Pharmacology and Bioinformatics.基于网络药理学和生物信息学的西黄丸治疗胰腺癌潜在分子机制研究
Evid Based Complement Alternat Med. 2022 Apr 11;2022:4651432. doi: 10.1155/2022/4651432. eCollection 2022.
9
Based on BATMAN-TCM to Explore the Molecular Mechanism of Xihuang Pill Regulating Immune Function to Treat Breast Precancerous Lesions.基于BATMAN-TCM探讨西黄丸调节免疫功能治疗乳腺导管上皮不典型增生的分子机制。 （注：原文中“Breast Precancerous Lesions”准确的医学术语应该是“乳腺导管上皮不典型增生”，更符合医学语境表述，这里按照准确术语给出译文，若严格按原文翻译则为“乳腺癌前病变” ）
Breast Cancer (Dove Med Press). 2021 Dec 23;13:725-742. doi: 10.2147/BCTT.S339607. eCollection 2021.
10
Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.整合网络药理学与实验验证探索左金丸治疗胰腺癌的作用机制。
Drug Des Devel Ther. 2021 Sep 4;15:3749-3764. doi: 10.2147/DDDT.S323360. eCollection 2021.
在局部晚期乳腺癌中，将紫杉烷添加到以蒽环类药物为基础的新辅助化疗中的效果。
Med Glas (Zenica). 2019 Feb 1;16(1):77-82. doi: 10.17392/964-19.
4
ASO Author Reflections: Elimination of Breast Cancer Surgery in Complete Responders After Neoadjuvant Chemotherapy: Imaging Perspective.ASO作者反思：新辅助化疗后完全缓解者的乳腺癌手术取消：影像学视角
Ann Surg Oncol. 2018 Dec;25(Suppl 3):628-629. doi: 10.1245/s10434-018-6780-3. Epub 2018 Sep 22.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.阿帕替尼与卡培他滨（希罗达）联用与卡培他滨（希罗达）单药用于晚期三阴性乳腺癌三线治疗的比较：一项回顾性研究。
Medicine (Baltimore). 2018 Sep;97(36):e12222. doi: 10.1097/MD.0000000000012222.
7
Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.参麦注射液治疗晚期非小细胞肺癌化疗患者癌因性疲乏：一项随机对照试验的研究方案
Trials. 2018 Sep 4;19(1):474. doi: 10.1186/s13063-018-2845-7.
8
Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time.乳腺癌放射治疗的晚期并发症：技术的演变及随时间变化的风险
Gland Surg. 2018 Aug;7(4):371-378. doi: 10.21037/gs.2018.01.05.
9
Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.2018 年巴西乳腺外科学会专家组推荐的乳腺癌新辅助治疗。
Breast Cancer Res Treat. 2018 Nov;172(2):265-272. doi: 10.1007/s10549-018-4912-x. Epub 2018 Aug 11.
10
Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers.中药在人类癌症中的个体化治疗应用。
Am J Chin Med. 2018;46(5):953-970. doi: 10.1142/S0192415X18500507. Epub 2018 Jul 9.